
This article from Bain & Company, "How to Successfully Scale Generative AI in Pharma," outlines the critical shift pharmaceutical companies must make from isolated generative AI experiments to a comprehensive, enterprise-wide strategy.
It highlights that a significant portion of pharma executives are already incorporating expected savings from generative AI into their budgets and actively developing use cases, moving beyond mere ideation.
The article stresses that true leaders will distinguish themselves by scaling winning applications across their operations, driven by a strategic operating model that prioritises high-value opportunities.
To achieve this, companies need a three-pronged approach: defining their strategic posture for decision-making and funding, leading through change with strong internal champions, and building foundational support through talent acquisition, strategic partnerships, and a robust ethical and regulatory framework.
Related Articles
Beyond the Mass Email: The Imperative of Personalization in Pharma
Why HCPs are tuning out generic communications and how personalization is transforming engagement.
Pharma Marketing: What's Working for HCPs in 2025
Key insights from pharma marketing leaders on effective HCP engagement strategies.
How Omnichannel is Transforming Pharma Engagement
The digital transformation journey and its impact on healthcare provider relationships.